Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor

Journal of Medicinal Chemistry

Volumn 57, Issue 1, 2014, Pages 98-109

  Kwiatkowska, Anna ^a   Couture, Frédéric ^a   Levesque, Christine ^a   Ly, Kévin ^a   Desjardins, Roxane ^a   Beauchemin, Sophie ^a   Prahl, Adam ^b   Lammek, Bernard ^b   Neugebauer, Witold ^a   Dory, Yves L ^a   Day, Robert ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITY OF GDA SK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE; LEUCINE; PROPROTEIN CONVERTASE 4 INHIBITOR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG SPECIFICITY; DRUG STABILITY; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DESIGN; DRUG STABILITY; FEMALE; HUMANS; MALE; MICE; PROPROTEIN CONVERTASES; PROTEASE INHIBITORS; SERINE ENDOPEPTIDASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84892609855     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401457n     Document Type: Article

References (35)

1. Fugere, M.; Day, R. Cutting back on pro-protein convertases: The latest approaches to pharmacological inhibition Trends Pharmacol. Sci. 2005, 26, 294-301
2. Hosaka, M.; Nagahama, M.; Kim, W. S.; Watanabe, T.; Hatsuzawa, K.; Ikemizu, J.; Murakami, K.; Nakayama, K. Arg-X-Lys/Arg-Arg motif as a signal for precursor cleavage catalyzed by furin within the constitutive secretory pathway J. Biol. Chem. 1991, 266, 12127-12130
3. Pasquato, A.; Pullikotil, P.; Asselin, M. C.; Vacatello, M.; Paolillo, L.; Ghezzo, F.; Basso, F.; Di Bello, C.; Dettin, M.; Seidah, N. G. The proprotein convertase SKI-1/S1P. In vitro analysis of Lassa virus glycoprotein-derived substrates and ex vivo validation of irreversible peptide inhibitors J. Biol. Chem. 2006, 281, 23471-23481
4. Benjannet, S.; Rhainds, D.; Essalmani, R.; Mayne, J.; Wickham, L.; Jin, W.; Asselin, M. C.; Hamelin, J.; Varret, M.; Allard, D.; Trillard, M.; Abifadel, M.; Tebon, A.; Attie, A. D.; Rader, D. J.; Boileau, C.; Brissette, L.; Chretien, M.; Prat, A.; Seidah, N. G. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol J. Biol. Chem. 2004, 279, 48865-48875
5. Couture, F.; D'Anjou, F.; Day, R. On the cutting edge of proprotein convertase pharmacology: From molecular concepts to clinical applications Biomol. Concepts 2011, 2, 421-438
6. Taylor, N. A.; Van De Ven, W. J.; Creemers, J. W. Curbing activation: Proprotein convertases in homeostasis and pathology FASEB J 2003, 17, 1215-1227
7. Seidah, N. G.; Prat, A. The biology and therapeutic targeting of the proprotein convertases Nat. Rev. Drug Discovery 2012, 11, 367-383
8. Anderson, E. D.; Thomas, L.; Hayflick, J. S.; Thomas, G. Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant J. Biol. Chem. 1993, 268, 24887-24891
9. Cameron, A.; Appel, J.; Houghten, R. A.; Lindberg, I. Polyarginines are potent furin inhibitors J. Biol. Chem. 2000, 275, 36741-36749
10. Fugere, M.; Appel, J.; Houghten, R. A.; Lindberg, I.; Day, R. Short polybasic peptide sequences are potent inhibitors of PC5/6 and PC7: Use of positional scanning-synthetic peptide combinatorial libraries as a tool for the optimization of inhibitory sequences Mol. Pharmacol. 2007, 71, 323-332
11. Becker, G. L.; Sielaff, F.; Than, M. E.; Lindberg, I.; Routhier, S.; Day, R.; Lu, Y.; Garten, W.; Steinmetzer, T. Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics J. Med. Chem. 2010, 53, 1067-1075
12. Becker, G. L.; Lu, Y.; Hardes, K.; Strehlow, B.; Levesque, C.; Lindberg, I.; Sandvig, K.; Bakowsky, U.; Day, R.; Garten, W.; Steinmetzer, T. Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases J. Biol. Chem. 2012, 287, 21992-22003
13. Jiao, G. S.; Cregar, L.; Wang, J.; Millis, S. Z.; Tang, C.; O'Malley, S.; Johnson, A. T.; Sareth, S.; Larson, J.; Thomas, G. Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 19707-19712
14. Senzer, N.; Barve, M.; Kuhn, J.; Melnyk, A.; Beitsch, P.; Lazar, M.; Lifshitz, S.; Magee, M.; Oh, J.; Mill, S. W.; Bedell, C.; Higgs, C.; Kumar, P.; Yu, Y.; Norvell, F.; Phalon, C.; Taquet, N.; Rao, D. D.; Wang, Z.; Jay, C. M.; Pappen, B. O.; Wallraven, G.; Brunicardi, F. C.; Shanahan, D. M.; Maples, P. B.; Nemunaitis, J. Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer Mol. Ther. 2012, 20, 679-686
15. Crunkhorn, S. Trial watch: PCSK9 antibody reduces LDL cholesterol Nat. Rev. Drug Discovery 2012, 11, 11
16. Khatib, A. M.; Siegfried, G.; Prat, A.; Luis, J.; Chretien, M.; Metrakos, P.; Seidah, N. G. Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: Importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions J. Biol. Chem. 2001, 276, 30686-30693
17. Maquoi, E.; Noel, A.; Frankenne, F.; Angliker, H.; Murphy, G.; Foidart, J. M. Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor FEBS Lett. 1998, 424, 262-266
18. Remacle, A. G.; Gawlik, K.; Golubkov, V. S.; Cadwell, G. W.; Liddington, R. C.; Cieplak, P.; Millis, S. Z.; Desjardins, R.; Routhier, S.; Yuan, X. W.; Neugebauer, W. A.; Day, R.; Strongin, A. Y. Selective and potent furin inhibitors protect cells from anthrax without significant toxicity Int. J. Biochem. Cell Biol. 2010, 42, 987-995
19. Coppola, J. M.; Bhojani, M. S.; Ross, B. D.; Rehemtulla, A. A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness Neoplasia 2008, 10, 363-370
20. Komiyama, T.; Coppola, J. M.; Larsen, M. J.; van Dort, M. E.; Ross, B. D.; Day, R.; Rehemtulla, A.; Fuller, R. S. Inhibition of furin/proprotein convertase-catalyzed surface and intracellular processing by small molecules J. Biol. Chem. 2009, 284, 15729-15738
21. D'Anjou, F.; Routhier, S.; Perreault, J. P.; Latil, A.; Bonnel, D.; Fournier, I.; Salzet, M.; Day, R. Molecular validation of PACE4 as a target in prostate cancer Transl. Oncol. 2011, 4, 157-172
22. Couture, F.; D'Anjou, F.; Desjardins, R.; Boudreau, F.; Day, R. Role of proprotein convertases in prostate cancer progression Neoplasia 2012, 14, 1032-1042
23. Levesque, C.; Fugere, M.; Kwiatkowska, A.; Couture, F.; Desjardins, R.; Routhier, S.; Moussette, P.; Prahl, A.; Lammek, B.; Appel, J. R.; Houghten, R. A.; D'Anjou, F.; Dory, Y. L.; Neugebauer, W.; Day, R. The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells J. Med. Chem. 2012, 55, 10501-10511
24. Judkins, B. D.; Allen, D. G.; Cook, T. A.; Evans, B.; Sardharwala, T. E. A versatile synthesis of amidines from nitriles via amidoximes Synth. Commun. 1996, 26, 4351-4367
25. Schweinitz, A.; Sturzebecher, A.; Sturzebecher, U.; Schuster, O.; Sturzebecher, J.; Steinmetzer, T. New substrate analogue inhibitors of factor Xa containing 4-amidinobenzylamide as P1 residue: Part 1 Med. Chem. 2006, 2, 349-361
26. Jeon, H. B.; Lee, Y.; Qiao, C.; Huang, H.; Sayre, L. M. Inhibition of bovine plasma amine oxidase by 1,4-diamino-2-butenes and -2-butynes Bioorg. Med. Chem. 2003, 11, 4631-4641
27. Busnel, O.; Bi, L.; Dali, H.; Cheguillaume, A.; Chevance, S.; Bondon, A.; Muller, S.; Baudy-Floc'h, M. Solid-phase synthesis of "mixed" peptidomimetics using Fmoc-protected aza-beta3-amino acids and alpha-amino acids J. Org. Chem. 2005, 70, 10701-10708
28. Morrison, J. F. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors Biochim. Biophys. Acta 1969, 185, 269-286
29. Williams, J. W.; Morrison, J. F. The kinetics of reversible tight-binding inhibition Methods Enzymol. 1979, 63, 437-467
30. Pauletti, G. M.; Gangwar, S.; Siahaan, T. J.; Aube, J.; Borchardt, R. T. Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies Adv. Drug Delivery Rev. 1997, 27, 235-256
31. Kacprzak, M. M.; Peinado, J. R.; Than, M. E.; Appel, J.; Henrich, S.; Lipkind, G.; Houghten, R. A.; Bode, W.; Lindberg, I. Inhibition of furin by polyarginine-containing peptides: Nanomolar inhibition by nona- d -arginine J. Biol. Chem. 2004, 279, 36788-36794
32. Becker, G. L.; Hardes, K.; Steinmetzer, T. New substrate analogue furin inhibitors derived from 4-amidinobenzylamide Bioorg. Med. Chem. Lett. 2011, 21, 4695-4697
33. Fields, G. B.; Noble, R. L. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids Int. J. Pept. Protein Res. 1990, 35, 161-214
34. Fugere, M.; Limperis, P. C.; Beaulieu-Audy, V.; Gagnon, F.; Lavigne, P.; Klarskov, K.; Leduc, R.; Day, R. Inhibitory potency and specificity of subtilase-like pro-protein convertase (SPC) prodomains J. Biol. Chem. 2002, 277, 7648-7656
35. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108